Hydrograph aids LEAP lung cancer test with graphene

Ms. Kjirstin Breure reports HYDROGRAPH PARTNERS WITH HAWKEYE BIO TO POWER NOVEL GRAPHENE BIOSENSOR SOLUTION FOR LEAP™ LUNG CANCER TEST FROM EASE HEALTHCARE Hydrograph Clean Power Inc.'s HydroGraph Inc. has noted its role in a new lung cancer screening product underpinning a collaboration between Hawkeye Bio (Torrance, Calif.) and Ease Healthcare (Pasadena, Calif.). Under a new commercialization agreement, Ease Healthcare will market the LEAP (lung enzyme activity profile) early detection test that incorporates HydroGraph's patented fractal graphene. LEAP is a non-invasive, radiation-free and highly sensitive blood test designed to detect early signs of lung cancer, even in asymptomatic patients and across all subtypes. Initially targeting high-risk populations including older smokers, military personnel, firefighters and first responders, the test has demonstrated a 99.8-per-cent negative predictive value, significantly improving early detection outcomes. HydroGraph's explosion synthesis technology produces ultrapure graphene that forms the foundation of Hawkeye Bio's patented biosensor which measures enzymatic activity associated with inflammatory disease -- a key biomarker in early stage cancer detection. "This partnership underscores the medical potential of high-purity graphene," said Kjirstin Breure, president and chief executive officer of HydroGraph. "Our ability to deliver graphene at scale supports groundbreaking diagnostics like Hawkeye's biosensors and Ease's LEAP test, ultimately saving lives through earlier detection and intervention." Lung cancer is the leading cause of cancer deaths, with the American Cancer Society estimating nearly 125,000 deaths and 227,000 new cases in the United States in 2025. Screening compliance remains low, with between 2 per cent and 6 per cent of at-risk individuals undergoing recommended low-dose CT scans annually, despite evidence that early detection is associated with significantly better five-year survival rates. "In addition to tobacco use, e xposure to environmental pollutants and workplace carcinogens can significantly increase one's risk of getting lung cancer," said Andre de Fusco, chief executive officer and co-founder of Hawkeye Bio. "Improved compliance with lung cancer screening guidelines may lead to earlier detection and improve radiotherapy and surgical outcomes. Our nano-scale graphene biosensors allow Ease Healthcare to bring LEAP testing to primary care physicians as a cost-effective diagnostic solution they can use in routine medical visits." Hawkeye Bio is the first company to manufacture nanoscale graphene biosensors for clinical cancer detection and holds global patents across the United States, United Kingdom, European Union, Japan, Korea, Hong Kong and Taiwan. The company aims to substantially reduce lung cancer mortality by offering a patient-safe, affordable solution to achieve population-scale lung cancer screening compliance for at-risk individuals. Presently 15 million to 19.3 million individuals in the U.S. should be screened annually for lung cancer. Hawkeye Bio projects this eligible population to increase as national screening guidelines evolve to incorporate additional risk factors beyond smoking history. Future LEAP platforms will plan to address 14 cancers, neurodegenerative disease (Alzheimer's) and inflammatory conditions such as multiple sclerosis. About Hydrograph Clean Power Inc. Hydrograph is a leading producer of pristine graphene using an "explosion synthesis" process, which allows for exceptional purity, low energy use and identical batches. The quality, performance and consistency of Hydrograph's graphene meets the Graphene Council's verified graphene producer standards, which very few companies worldwide achieve. We seek Safe Harbor.